📰 Nasdaq Cccc News
Page 2 - Nasdaq Cccc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Cccc. Real-time updates on events, politics, business and more.
October 4, 2023
C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has been given a consensus recommendation of “Hold” by the seven research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and two have issued a buy recommendation on the […]
September 5, 2023
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
August 31, 2023
The stock of C4 Therapeutics Inc. (CCCC) has seen a -11.48% decrease in the past week, with a -21.02% drop in the past month, and a -13.57% decrease in the past quarter. The volatility ratio for the week is 4.37%, and the volatility levels for the past 30 days are at 4.53% for CCCC. The simple movin
July 25, 2023
C4 Therapeutics (NASDAQ:CCCC – Free Report) had its price objective decreased by UBS Group from $22.00 to $20.00 in a research note published on Friday, FlyOnTheWall reports. Several other analysts have also commented on the stock. Evercore ISI lowered their price objective on shares of C4 Therapeutics to $10.00 in a report on Tuesday, May […]
July 21, 2023
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) had its price objective decreased by UBS Group from $22.00 to $20.00 in a report issued on Friday, FlyOnTheWall reports. UBS Group’s price target would indicate a potential upside of 468.18% from the stock’s current price. Several other equities research analysts have also issued reports on the company. […]
June 26, 2023
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) have received an average recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. […]
June 3, 2023
C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target lowered by Evercore ISI to $10.00 in a report released on Tuesday morning, The Fly reports. Several other research firms also recently weighed in on CCCC. Credit Suisse Group raised shares of C4 Therapeutics from an underperform rating to a neutral rating and decreased their […]
June 1, 2023
C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has been assigned an average rating of “Hold” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company. The […]
May 30, 2023
C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average […]
May 12, 2023
C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target cut by HC Wainwright from $35.00 to $25.00 in a research report report published on Monday, The Fly reports. HC Wainwright also issued estimates for C4 Therapeutics’ FY2023 earnings at ($2.84) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.42) EPS, FY2026 earnings at […]